Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Men
NCT05754411Phase 1Completed
- Sponsor
- ACEA Pharmaceuticals
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olgotrelvir in coronavirus disease 2019 (COVID-19), sponsored by ACEA Pharmaceuticals. Primary endpoints: Distribution Ratio of Total Radioactivity in Whole Blood and Plasma, Total Radioactivity in Whole Blood and Plasma: AUC[0-t] and AUC[0-inf] and 5 more. Started May 2023; status: completed.
02
Drugs
olgotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05754411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05754411.